bluebird bio Announces First Patient with Sickle Cell Disease...

This patient is enrolled in the HGB-205 Study being conducted in Paris, France. bluebird has also opened a separate US-based trial in the United States for the treatment of up to 8 severe sickle cell disease patients with the company's LentiGlobin BB305 drug product.

http://ift.tt/1r0T2oD